Metabolomic characteristics of cholesterol-induced non-obese nonalcoholic fatty liver disease in mice

• Published in: Scientific reports Vol. 7; no. 1; pp. 6120 - 14
• Main Authors: Tu, Lan N, Showalter, Megan R, Cajka, Tomas, Fan, Sili, Pillai, Viju V, Fiehn, Oliver, Selvaraj, Vimal
• Format: Journal Article
• Language: English
• Published: England Nature Publishing Group 21.07.2017; Nature Publishing Group UK; Nature Portfolio
• Subjects: Animals; Bile Acids and Salts; Biomarkers; Body weight; Cholesterol; Cholesterol - metabolism; Cholic acid; Diet, High-Fat; Disease Models, Animal; Esters; Etiology; Fatty liver; Female; Gas Chromatography-Mass Spectrometry; Hepatitis; Lipid Metabolism; Liquid chromatography; Liver diseases; Male; Mass spectroscopy; Metabolic syndrome; Metabolism; Metabolites; Metabolome; Metabolomics; Metabolomics - methods; Mice; Non-alcoholic Fatty Liver Disease - etiology; Non-alcoholic Fatty Liver Disease - metabolism; Non-alcoholic Fatty Liver Disease - pathology; Rodents; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Steatosis
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-017-05040-6

Nonalcoholic fatty liver disease (NAFLD) in non-obese patients remains a clinical condition with unclear etiology and pathogenesis. Using a metabolomics approach in a mouse model that recapitulates almost all the characteristic features of non-obese NAFLD, we aimed to advance mechanistic understanding of this disorder. Mice fed high fat, high cholesterol, cholate (HFHCC) diet for three weeks consistently developed hepatic pathology similar to NAFLD and nonalcoholic steatohepatitis (NASH) without changes to body weight or fat pad weights. Gas- and liquid chromatography/mass spectrometry-based profiling of lipidomic and primary metabolism changes in the liver and plasma revealed that systemic mechanisms leading to steatosis and hepatitis in this non-obese NAFLD model were driven by a combination of effects directed by elevated free cholesterol, cholesterol esters and cholic acid, and associated changes to metabolism of sphingomyelins and phosphatidylcholines. These results demonstrate that mechanisms underlying cholesterol-induced non-obese NAFLD are distinct from NAFLD occurring as a consequence of metabolic syndrome. In addition, this investigation provides one of the first metabolite reference profiles for interpreting effects of dietary and hepatic cholesterol in human non-obese NAFLD/NASH patients.